Curriculum vitae 2014: Øyvind Sverre Bruland

Vennerhagen, Sørkedalen 982, N-0758 OSLO, Norway
Born: December 14, 1952 in Oslo, Norway. *Civil Status*: Cohabitant, 3 children
E.mail: oyvind.bruland@medisin.uio.no **Web:** www.bruland.info

EDUCATION: 1971-76: Studies in Chemistry, Mathematics, Biology and Zoology, University of Trondheim and University of Oslo. 1976 : Cand.Mag. (**Bachelor of Science**), University of Oslo. 1974-79: Medical studies at University of Oslo. 1979: Cand. Med. (**M.D.**), University of Oslo. 1989: Dr. Med. (**Ph.D.**), University of Oslo

LATEST POSITIONS HELD:

- 1996-2004: **Sect. Head & Consult. Oncologist**, Dept. of Oncology, DNR
- 1999-2002: **Professor of Clinical Oncology**, University of Tromsø
- 2000-02: Scientific Chairman, 18th. UICC World Cancer Congress
- 2002-08: **Professor of Clinical Oncology**, University of Oslo
- 2003-06: Head of Clinical Research, Center for Research & Training in Radiation Oncology
- 2004 (January-May): Visiting Professor, Dept. of Pediatrics, Memorial Sloan Kettering Cancer Center, New York
- 2004-present: **Senior Consultant Oncologist,** Dept. of Oncology, DNR
- 2005-2013: **Professor of Comparative Oncology**, (adjunct position), The Norwegian School of Veterinary Medicine, Oslo
- 2008-present: **Professor of Clinical Oncology** (Tenure position) University of Oslo

SCIENTIFIC MERITS:

- Publications: 153 papers in peer-reviewed international journals. In addition several editorials, reviews and book-chapters etc. For a complete list see List of Publications at www.bruland.info
- On the "Editorial Board" of three scientific international journals
- Holds five international patents related to targeted radionuclide therapies
- Founder of Algeta ASA in 1997 together with Roy H. Larsen – Their lead product Alpharadin (Radium-223); currently marketed by Bayer as Xofigo, was approved by FDA & EMA, 2013 for patients with skeletal metastases from prostate cancer. Phase-2 studies in breast cancer are ongoing
- 2008 – Elected member of The Norwegian Academy of Science and Letters – Det Norske Videnskaps-Akademi
- 2009 – Co-founder of Nordic Nanovectors A/S Oslo (with Medinnova)
- 2010 – Co-founder of Oncoinvent A/S, Oslo (with Inven2)
- 2014 – Granted "The Innovation Price", Univeristy of Oslo; shared with Roy H Larsen

Research Supervision – Completed Theses: Main supervisor or co-supervisor for 16 candidates having completed their theses. Currently main supervisor for one candidate: Kjetil Berner, and co-supervisor for 3 PhD students: Tale Barøy, Kristin Anfinsen and Ada Repetto (submitted).